Newsroom | 35696 results

LOS ANGELES--(BUSINESS WIRE)--City of Hope® CEO Robert Stone, who leads one of the largest and most advanced cancer research and treatment organizations in the United States, has been recognized as one of the most influential leaders by two top health care trade publications: Modern Healthcare and Becker’s Hospital Review. Stone was honored for expanding access to advanced cancer care nationwide, advancing breakthrough cancer research, and developing a national network of lifesaving clinical tr...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（Nasdaq: ONC; HKEX: 06160; SSE: 688235）は、フロリダ州オーランドで開催される第67回ASH年次総会・展示会において、血液領域のポートフォリオの深み、質、勢いを示すことで、慢性リンパ性白血病（CLL）におけるイノベーションのリーダーという同社の立場を改めて示します。BeOneのASHデータ全体は、BRUKINSA ®（ザヌブルチニブ）が、ブルトン型チロシンキナーゼ阻害薬（BTKi）の基盤となる選択肢であることを裏付けています。 「ASH 2025では、BRUKINSAの強みとBGB-16673の可能性の両方を浮き彫りにする、当社のCLLフランチャイズ全体にわたる新たなデータを発表します」と、BeOneの血液領域チーフ・メディカル・オフィサー（CMO）であるアミット・アガルワル医学博士は述べています。「CLLにおいては長期データがゴールドスタンダードであり、BRUKINSAは、患者と医師...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents to present new CTO1681 data at the ESMO Immuno-Oncology Congress 2025....

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post‑RP) for patients experiencing biochemical recurrence (BCR) following radical prostatectomy. The test builds on the established ArteraAI platform and delivers prognostic results and insights into short-term ADT benefit to optimize decision-making in the salvage therapy setting, where additional treatment is gi...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa internacional de tratamientos oncológicos, reafirma su posición como líder en innovación en el campo de la leucemia linfocítica crónica (LLC) al demostrar la solidez, la calidad y el dinamismo de su cartera de productos hematológicos en la 67.a reunión y exposición anual de la ASH (ASH Annual Meeting and Exposition) en Orlando, Florida. La totalidad de los datos de BeOne presentado...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas. “This year at SABCS, our research highlights the power of multimodal data to help unravel the complexity of breast cancer,” said Ez...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer....

SAN CARLOS, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, behauptet seine Position als Innovationsführer auf dem Gebiet der chronischen lymphozytischen Leukämie (CLL) durch die Demonstration der Tiefe, Qualität und Dynamik seines Hämatologie-Portfolios beim 67. ASH Annual Meeting and Exposition in Orlando, US-Bundesstaat Florida. Die Gesamtheit der ASH-Daten von BeOne stützt BRUKINSA® (Zanubrutinib) als fundam...

PALO ALTO, Calif. & ROME--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation, today announced the appointment of Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath to its board of directors. Dr. Kelsey is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, re...